Highlights
- Successfully completes POC testing for first ever scalable production of ApoTainer™
- Cellect’s ApoTainer™ built to replace complex laboratory procedures for stem cell extraction at a fraction of the time and cost
- Dr. Shai Yarkoni, Cellect CEO commented: “We believe that the expected demand for stem cells as raw material for regenerative medicine will explode over the next five years. Our ApoTainer™ is intended to ensure this demand is met with a cost-effective quality manufacturing of stem cells.”
- The ApoTainer™ is covered by a portfolio of IP including a patent application for apoptotic selection of stem cells using FasL-coated magnetic beads
Pompano Beach, FL, March 13, 2018 — 
MELBOURNE, Australia, Feb. 27, 2018 — Australian stem cell and regenerative medicine company, 
January 29, 2018 – Nikon Corporation (Kazuo Ushida, President, Tokyo) has announced a business alliance agreement (hereinafter referred to as the “agreement”) with Advanced Cell Technology and Engineering Ltd. (Koichi Otomo, President, Tokyo, hereinafter referred to as “ACTE”) in order to establish a clinical-use master cell bank (MCB)*1, to be employed for regenerative medicine products derived from dental pulp cells*2.